AKBA FY 2024 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AKBAAkebia Therapeutics, Inc.

$365M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$160M-17.7% YoY

Gross Profit

$97M60.6% margin

Operating Income

-$50M-31.5% margin

Net Income

-$69M-43.3% margin

EPS (Diluted)

$-0.33

Cash Flow

Operating Cash Flow

-$41M

Free Cash Flow

-$41M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$221M

Total Liabilities

$270M

Stockholders' Equity

-$49M

Cash & Equivalents

$52M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$160M	$195M	-17.7%
Gross Profit	$97M	$120M	-19.5%
Operating Income	-$50M	-$46M	-9.1%
Net Income	-$69M	-$52M	-33.7%